December 2023: Hyperhidrosis updates

News

December 2023: Hyperhidrosis updates


Commissioning Policy

The routine commissioning of botulinum toxin A for the management of hyperhidrosis is accepted in Devon for patients with severe axillary hyperhidrosis. Patients must have a Hyperhidrosis Disease Severity Scale (HDSS) score of 3 or 4 (sweating is barely tolerable/intolerable and frequently/always interferes with daily activities) despite at least six weeks of topical aluminium chloride and self-management strategies, AND a resting sweat production of at least 100mg/5 minutes (per axilla).

Revised formulary guidance

The hyperhidrosis guidance has been updated to incorporate the oral treatments, oxybutynin (off-label) and propantheline, for the management of primary and secondary hyperhidrosis.

Drug changes

Oxybutynin, immediate-release and modified-release (off-label), and propantheline 15mg tablets have been reclassified from amber (specialist input) to blue (second line) for the treatment of hyperhidrosis.

See here for other updates to the formulary